Pocenbrodib

N/A

Report date: 2025/03/26 15:58:10
NME

Base Information

Drug NamePocenbrodib
Drug Alias NameFT-7051P-300
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of Actionp300-CBP transcription factors inhibitors
Targetsp300-CBP transcription factors
Therapy Area/IndicationsProstatic DiseasesMale Urogenital DiseasesProstatic Neoplasms, Castration-Resistant +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesForma Therapeutics Holdings Inc
China Registration ClassN/A

Develop Information

Active CompaniesPathos AI Inc
Inactive CompaniesNovo Nordisk A/S
Active IndicationsProstatic DiseasesProstatic Neoplasms, Castration-ResistantProstatic Neoplasms +[5] 
Inactive IndicationsMale Urogenital DiseasesNeoplasms

Other Information

ATC CodeN/A
Related LinksKEGG